Expanding Hospital Exemptions For ATMPs Could Make Europe Less Attractive To Investors

Rather than increasing access to medicines, expanding the hospital exemption provision for advanced therapy medicinal products (ATMPs) as part of the European Commission’s pharmaceutical legislative overhaul could make industry less inclined to launch such products in the EU.

This warning was issued by speakers at a recent symposium hosted by the Alliance For Regenerative Medicines (ARM), which represents small and large companies, academic